i-SENS Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de i-SENS ont diminué à un taux annuel moyen de -30.9%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 17.7% par an. Les revenus ont augmenté de en à un taux moyen de 8.8% par an.

Informations clés

-30.9%

Taux de croissance des bénéfices

-30.9%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie	22.7%
Taux de croissance des recettes	8.8%
Rendement des fonds propres	-1.2%
Marge nette	-1.3%
Dernière mise à jour des bénéfices	30 Jun 2024

Mises à jour récentes des performances passées

i-SENS' (KOSDAQ:099190) Conservative Accounting Might Explain Soft Earnings

Mar 27

Does i-SENS's (KOSDAQ:099190) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 15

Recent updates

What i-SENS, Inc.'s (KOSDAQ:099190) P/S Is Not Telling You

Nov 27

i-SENS, Inc. (KOSDAQ:099190) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Aug 05

If You Had Bought i-SENS' (KOSDAQ:099190) Shares Five Years Ago You Would Be Down 27%

Jan 18

Do Its Financials Have Any Role To Play In Driving i-SENS, Inc.'s (KOSDAQ:099190) Stock Up Recently?

Jan 05

Is It Worth Considering i-SENS, Inc. (KOSDAQ:099190) For Its Upcoming Dividend?

Dec 24

Does i-SENS's (KOSDAQ:099190) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 15

i-SENS (KOSDAQ:099190) Could Easily Take On More Debt

Dec 02

Does i-SENS, Inc. (KOSDAQ:099190) Have A Place In Your Dividend Portfolio?

Nov 20

Ventilation des recettes et des dépenses

Comment i-SENS gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

KOSDAQ:A099190 Recettes, dépenses et bénéfices (KRW Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
30 Jun 24	280,288	-3,531	71,017	30,053
31 Mar 24	272,877	-766	67,222	27,780
31 Dec 23	265,120	3,709	62,700	26,995
30 Sep 23	255,913	4,843	60,049	27,380
30 Jun 23	257,387	7,696	55,011	27,205
31 Mar 23	256,661	7,352	54,096	27,170
31 Dec 22	264,837	16,138	53,631	26,974
30 Sep 22	262,067	20,078	49,013	25,364
30 Jun 22	252,562	25,059	46,842	23,708
31 Mar 22	249,178	31,504	44,738	23,399
31 Dec 21	232,935	25,451	41,798	21,891
30 Sep 21	225,758	29,923	44,072	20,652
30 Jun 21	217,293	29,022	42,044	19,705
31 Mar 21	211,667	27,286	42,035	19,316
31 Dec 20	203,708	26,839	41,672	18,915
30 Sep 20	201,817	17,606	38,020	19,166
30 Jun 20	199,980	19,878	38,003	17,951
31 Mar 20	193,528	24,733	36,742	16,484
31 Dec 19	189,844	23,426	35,643	15,918
30 Sep 19	184,139	33,949	33,972	14,473
30 Jun 19	181,109	32,287	34,653	14,238
31 Mar 19	175,627	24,622	35,228	13,866
31 Dec 18	172,997	22,619	34,620	13,352
30 Sep 18	168,333	18,247	35,147	13,816
30 Jun 18	162,795	15,450	32,647	13,877
31 Mar 18	159,320	16,437	30,159	13,779
31 Dec 17	156,964	15,730	29,694	13,607
30 Sep 17	150,725	16,808	27,146	13,134
30 Jun 17	144,108	18,050	25,401	12,484
31 Mar 17	139,709	16,295	24,525	12,305
31 Dec 16	132,468	17,561	22,399	11,833
30 Sep 16	121,640	17,066	19,670	11,486
30 Jun 16	113,583	15,074	18,649	11,001
31 Mar 16	107,804	15,692	16,644	10,372
31 Dec 15	101,921	14,716	14,757	9,794
30 Sep 15	100,074	13,736	15,065	9,127
30 Jun 15	97,317	14,036	13,511	8,690
31 Mar 15	95,553	14,049	12,949	8,619
31 Dec 14	95,608	14,466	12,445	8,540
30 Sep 14	93,515	16,322	11,002	8,230
30 Jun 14	91,059	18,239	10,310	7,899
31 Mar 14	86,720	18,646	9,729	7,049
31 Dec 13	82,863	18,642	9,345	6,299

Des revenus de qualité: A099190 n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: A099190 n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: A099190 n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 30.9% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de A099190 au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: A099190 n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( -8.7% ).

Rendement des fonds propres

ROE élevé: A099190 a un retour sur capitaux propres négatif ( -1.2% ), car il n'est actuellement pas rentable.

i-SENS Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

First quarter 2024 earnings released: ₩10.00 loss per share (vs ₩153 profit in 1Q 2023)

i-SENS' (KOSDAQ:099190) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does i-SENS's (KOSDAQ:099190) Statutory Profit Adequately Reflect Its Underlying Profit?

Recent updates

What i-SENS, Inc.'s (KOSDAQ:099190) P/S Is Not Telling You

New minor risk - Share price stability

New major risk - Revenue and earnings growth

i-SENS, Inc. (KOSDAQ:099190) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Kwang Dong Pharmaceutical Co., Ltd. (KOSE:A009290) agreed to acquire 29.7% stake in Precision Biosensor, Inc. (KOSDAQ:A335810) from i-SENS, Inc. (KOSDAQ:A099190) from Cha, Geun Sik, Nam Hak-hyeon and Yoon Jongwoo for KRW 16.9 billion.

First quarter 2024 earnings released: ₩10.00 loss per share (vs ₩153 profit in 1Q 2023)

i-SENS, Inc. announced that it has received KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd

i-SENS, Inc. announced that it expects to receive KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd

i-SENS' (KOSDAQ:099190) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of ₩175 per share at 0.7% yield

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 40%

New major risk - Revenue and earnings growth

Price target increased by 25% to ₩27,500

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 17%

Price target decreased by 9.8% to ₩39,700

Upcoming dividend of ₩300 per share

Less than half of directors are independent

Consensus forecasts updated

Consensus EPS estimates fall by 10%

Price target increased to ₩40,500

Less than half of directors are independent

Upcoming dividend of ₩250 per share

Consensus forecasts updated

Estimating The Fair Value Of i-SENS, Inc. (KOSDAQ:099190)

Consensus forecasts updated

Investor sentiment improved over the past week

Do i-SENS's (KOSDAQ:099190) Earnings Warrant Your Attention?

Is i-SENS (KOSDAQ:099190) Using Too Much Debt?

Is i-SENS, Inc.'s (KOSDAQ:099190) 0.8% Dividend Worth Your Time?

i-SENS, Inc., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩25,050

Will i-SENS (KOSDAQ:099190) Multiply In Value Going Forward?

How Much Of i-SENS, Inc. (KOSDAQ:099190) Do Insiders Own?

If You Had Bought i-SENS' (KOSDAQ:099190) Shares Five Years Ago You Would Be Down 27%

New 90-day low: ₩26,450

Do Its Financials Have Any Role To Play In Driving i-SENS, Inc.'s (KOSDAQ:099190) Stock Up Recently?

Is It Worth Considering i-SENS, Inc. (KOSDAQ:099190) For Its Upcoming Dividend?

New 90-day high: ₩29,650

Does i-SENS's (KOSDAQ:099190) Statutory Profit Adequately Reflect Its Underlying Profit?

i-SENS (KOSDAQ:099190) Could Easily Take On More Debt

Does i-SENS, Inc. (KOSDAQ:099190) Have A Place In Your Dividend Portfolio?

Price target raised to ₩37,000

New 90-day high - ₩30,550

New 90-day high - ₩29,500

Price target lowered to ₩33,000

Ventilation des recettes et des dépenses

Historique des gains et des recettes

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Rendement des fonds propres

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé